| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $4.0M | +30.7% |
| Cost of Revenue | $2.8M | +11.2% |
| Gross Profit | $1.2M | +127.3% |
| R&D Expense | $6.9M | +22.9% |
| SG&A Expense | $5.6M | +25.5% |
| Operating Income | -$12.5M | -17.6% |
| Pre-tax Income | -$11.8M | -24.6% |
| Net Income | -$11.8M | -24.6% |
| EPS (Basic) | -$1.03 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $18.2M | +103.1% |
| Accounts Receivable | $1.5M | +10.1% |
| Inventory | $203K | -59.7% |
| Current Assets | $20.8M | +7.4% |
| Total Assets | $23.7M | +3.7% |
| Current Liabilities | $3.3M | +58.3% |
| Total Liabilities | $5.4M | +8.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$8.2M | +17.9% |
| Capital Expenditures | $53K | -53.1% |
| Investing Cash Flow | $7.6M | +249.4% |
| Financing Cash Flow | $9.8M | -28.9% |
| Free Cash Flow | -$8.3M | +18.3% |
| -5.1% |
| EPS (Diluted) | -$1.03 | -5.1% |
| Stockholders' Equity |
| $18.2M |
| +2.5% |